PubMed-compiled information sheet
This sheet was compiled from PubMed (NIH) abstracts using AI assistance. Every factual claim is cited to a real PubMed article (see the source list). It has not yet been human-reviewed — confirm with a healthcare provider before use.
Compiled from 30 PubMed articles · model: gemma4:31b
Summary
Background
Traditional uses
Active compounds
Mechanism of action
Clinical evidence
C. indicum improved loss of body weight, impaired glucose tolerance, and inhibited muscle protein degradation factors MAFbx and MuRF1 in mice [PMID:39624846].
A 0.5% water extract cosmetic cream was evaluated in human volunteers; extracts dose-dependently inhibited mushroom tyrosinase activity [PMID:26786567].
C. indicum was identified as having high xanthine oxidase inhibitory activity (>85%) [PMID:29628890].
Linarin, a principal constituent, attenuated hyperuricemic nephropathy in mouse models [PMID:39908585].
Dimeric guaianolide sesquiterpenoids from the flowers ameliorate hepatic steatosis by mitigating SIRT1-mediated lipid accumulation and ferroptosis [PMID:39788286].
Evidence summary
PubMed sources
- 1.PMID: 38009816 (2024) — Handelin alleviates cachexia- and aging-induced skeletal muscle atrophy by improving protein homeostasis and inhibiting inflammation. · Journal of cachexia, sarcopenia and muscle
- 2.PMID: 39788286 (2025) — Dimeric guaianolide sesquiterpenoids from the flowers of Chrysanthemum indicum ameliorate hepatic steatosis through mitigating SIRT1-mediated lipid accumulation and ferroptosis. · Journal of advanced research
- 3.PMID: 39908585 (2025) — Linarin attenuates hyperuricemic nephropathy by modulating Nrf2/Keap1 and TLR4/NF-κB signaling pathways: Linarin attenuates hyperuricemic nephropathy. · Phytomedicine : international journal of phytotherapy and phytopharmacology
- 4.PMID: 39624846 (2024) — Chrysanthemum indicum L. ameliorates muscle atrophy by improving glucose tolerance in CT26-induced cancer cachexia. · Frontiers in pharmacology
- 5.PMID: 29628890